Psylo is a biotechnology company focused on developing neuroplastogens, a new class of therapies aimed at restoring brain function by promoting the growth and remodeling of neural circuits. The company is particularly interested in the 5-HT2A serotonin receptor, which emerging research suggests could lead to innovative therapeutic approaches for treating central nervous system disorders. Psylo aims to address the scalability and accessibility challenges associated with existing treatments like psilocybin, which, despite their potential in treating mood disorders and addiction, face issues such as high costs, stigma, and regulatory constraints.

To achieve its goals, Psylo employs a computationally-enhanced drug discovery platform that allows for the design and development of novel neuroplastogens with optimized pharmacological profiles. This approach is intended to create rapid-acting serotonergic agents that are more widely accessible and devoid of the side effects and scalability issues linked to traditional psychedelics. Through its ongoing research and development efforts, Psylo is positioning itself at the forefront of the next generation of psychedelic therapies, aiming to make significant contributions to mental health treatment.

Australia

Psylo is a drug development company focused on next generation psychedelics; our goal is to make broadly accessible medicines as improved treatments to currently available SSRI medications, using psychedelic molecules as the starting point.  We are building a pipeline of novel molecules with the ultimate goal of taking leading candidates through to clinical trials.

Psylo

Company Details